Minimum reporting requirements for platelet-rich plasma in biomaterial research

Platelet-rich plasma (PRP) is gaining significant attention in regenerative medicine, offering an abundance of growth factors and bioactive molecules that promote tissue repair and healing. In biomaterial research, PRP is often incorporated into scaffolds to enhance their bioactivity, facilitating cell attachment, proliferation, and differentiation for improved tissue regeneration. However, inconsistencies in outcomes and variability across studies hinder its clinical translation. These challenges are primarily attributed to the lack of standardized reporting criteria for PRP characterization, which limits reproducibility and cross-study comparisons. Accurate characterization of PRP is essential for understanding its biological activity and therapeutic potential. Key parameters include platelet, white blood cell, and red blood cell concentrations. Recent classification systems, such as those proposed by the ISTH Subcommittee on Platelet Physiology, emphasize the importance of these parameters in categorizing PRP types. Establishing minimal reporting requirements helps address variability in PRP studies, ensuring consistency and transparency in the methodology and results. By adopting these standards as mandatory reporting requirements, researchers can reduce variability, enhance the credibility of their findings, and facilitate the development of standardized protocols for PRP-based therapies.